The Drug Regulatory Authority of Pakistan (DRAP) has initiated a voluntary recall of several batches of Amoxil Forte suspension and Amoxil suspension due to a defective induction seal, which may compromise product safety and hygiene. The manufacturer has proactively commenced the recall process after quality concerns emerged.

All pharmacists, healthcare professionals, and consumers are instructed to halt distribution immediately, quarantine any remaining stock, and return affected products to the supplier. Users who have purchased these suspensions are advised to consult a healthcare provider if any signs of contamination or seal tampering are observed.

This recall underlines DRAP’s commitment to protecting public health and maintaining strict medicine quality control standards. It also serves as a reminder of the importance of regulatory vigilance throughout pharmaceutical supply chains.